Compass Pathways reports durable depression trial data
Compass Pathways (NASDAQ:CMPS) announced Phase 3 clinical trial results demonstrating that its proprietary synthetic psilocybin compound, COMP360, provides durable therapeutic relief for treatment-resistant depression.











